Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Psychedelic Alpha, formerly known as Psilocybin Alpha, is an independent media, research, and advisory company focused on psychedelic medicines. The company provides data-driven news, analysis, premium intelligence products, and consultancy services covering drug development, regulation, policy, and commercialization in the psychedelics field. Its offerings include subscription research, advisory services, and public resources such as drug development, policy, and readout trackers. While it is not a drug developer itself, it serves pharmaceutical, healthcare, investor, philanthropic, and research stakeholders that need structured intelligence on the emerging psychedelic therapeutics market. Founded in 2020 by Josh Hardman, the company is based in Harrogate, North Yorkshire, United Kingdom.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Psychedelic Alpha.